OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator. This document is also available as Markdown.

← Mars Org. Ltd

2024-12-31-accounts

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

ANNUAL REPORT & FINANCIAL STATEMENTS

For the Year Ended 31 December

Registered Charity Number: 1152340

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

index

REFERENCE & ADMINISTRATIVE DETAILS

Trustees' annual report (incorporating the Directors' Report) .......................................4 to 19

Independent Auditor's Report to the members ................20 to 24

Statement of financial activities

Registered Company Number: 08321795

Registered Charity Number: 1152340 Registered Office:

New Burlington House, 1075 Finchley Road, London NW11 0PU

(including Income and Expenditure account) ......................25 Statement of financial position ....................................................26 Statement of cash flows ...................................................................27 Notes to the financial statements ..............................................28 to 35

Trustees: Rabbi H Grunfeld Mr J Herzka Mr P Weinberger

Bankers:

Auditors:

HSBC UK, 465 Bethnal Green Road Bethnal Green, London E2 9QW

Cohen Arnold

New Burlington House, 1075 Finchley Road, London NW11 0PU

Organisation Details:

MARS

Unit 15 Grosvenor Way, London, E5 9ND 020-3322-8586 www.marsorg.com - mail@marsorg.com

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

Who we are

our mission

MARS’ mission is to give every patient a chance to access the most advanced care available to enable a positive outcome.

After guiding two close relatives through critical illness, Rabbi Hershel Grunfeld became a lifeline for others facing similar struggles. As desperate families turned to him for support, the need for medical advocacy became painfully clear. By 2012, his ad-hoc efforts had grown into an official organization—one that has since evolved into a vital, multifaceted support network, offering hope and help to those in need.

n n n

what we do

Mars supports patients at every stage of their medical journey, striving for the best medical outcomes in all circumstances.

After a medical crisis, uncertainty sets in, families feel like they've been thrust into a foreign world. Complex terminology bombards them from all directions, and conflicting predictions leave them disoriented. They feel lost, isolated, and overwhelmed— trying to make sense of a reality they never saw coming.

We at MARS are here to ensure that every patient has access to the most advanced care available, giving them the best possible chance at a positive medical outcome. Above all, MARS is dedicated to easing each patient’s medical journey—guiding them through the often complex and overwhelming healthcare system with clarity.

MARS stands beside patients through their toughest moments, providing expert guidance, unwavering support, and the clarity they need to navigate the medical maze.

We bridge the gap between patients and their medical teams, ensuring clear communication, informed decision-making, and advocating for them when they need it most.

// 5

Year Ended 31 December 2024

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

how we do this

==> picture [262 x 14] intentionally omitted <==

----- Start of picture text -----
This mission is achieved by doing the following
----- End of picture text -----

==> picture [77 x 68] intentionally omitted <==

----- Start of picture text -----
Kevin Harrington
Professor of
Biological Cancer
Therapies at The
Institute of Cancer
Research
----- End of picture text -----

“My abiding interest in MARS, and my willingness to give time to it and support it, is because it’s there for patient benefit. Irrespective of where someone lives, where someone comes from or what their background is, they should always have access to the best medical advice and the best medical care. And because that’s not always the case, we need organisations that enable patients to receive that. To my mind the MARS organisation is exactly that.”

==> picture [185 x 109] intentionally omitted <==

----- Start of picture text -----
NETWORKING RESEARCH
=
ADVOCACY DIAGNOSTICS
----- End of picture text -----

NETWORKING

Partners

MARS collaborates with the NHS, hospitals, GPs, and welfare organizations, building strong relationships with top doctors and medical centres.

Networking

With global connections in Europe, Israel, and the USA, MARS ensures patients access the best care, regardless of location.

Awareness

With widespread campaigns in the community on important topics such as Private Medical Insurance, MARS has brought crucial information to the community's attention.

Training

MARS staff undergo continuous training in medical research, call handling, and staying updated on the latest advancements through global conferences. MARS also sponsors specialized medical training for local Hatzolo medics, boosting their life-saving skills.

REFERRALS

SUPPORT

==> picture [59 x 9] intentionally omitted <==

----- Start of picture text -----
RESEARCH
----- End of picture text -----

Pioneering Medical Advancements

MARS stays at the forefront of medicine, continuously researching the latest treatments, trials, and techniques.

Complex Disease Research

For atypical or unclear cases, MARS conducts in-depth medical research—exploring differential diagnoses, consulting top specialists, and ensuring each patient receives an accurate and timely diagnosis.

Novel Treatments Research

When conventional options are limited, MARS identifies cuttingedge therapies for rare or complex conditions—often uncovering advanced treatments not yet available in the UK and helping patients access them when appropriate.

6 // Trustees Annual Report

// 7

Year Ended 31 December 2024

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

REFERRALS

Targeted Referrals

MARS advisors go beyond finding the right specialist—they analyse each case in depth, considering factors like success rates, experience, care style, and access to advanced treatments to ensure the best possible match for every patient.

Second Opinions

We help patients obtain second (or even third and fourth) opinions from top specialists - both national and international - ensuring a comprehensive understanding of their best treatment options.

Complex Patient Care

Our support extends beyond referrals, guiding patients through acute and long-term health challenges. Complex cases often require a multi-disciplinary approach, with optimal care spread across multiple centres. MARS creates tailored plans that take all medical, logistical, and personal factors into account— guiding patients through acute and long-term health challenges with expertise.

Clinical Trial Enrolment

When conventional treatments fall short, MARS searches globally for appropriate clinical trials— often uncovering life-saving options for patients with limited or no alternatives. We streamline the process and help cut through red tape to support timely enrolment.

==> picture [79 x 57] intentionally omitted <==

----- Start of picture text -----
Mr Pranav Pandya
Consultant in Fetal
Medicine,
Director of Fetal
Medicine, UCLH
----- End of picture text -----

“It is a privilege to work with Rabbi Grunfeld and MARS. I have always found that MARS is committed to providing the highest standard of care. They support families at a time of need when there can be great anxiety and uncertainty. Rabbi Grunfeld takes time to understand the complexities of each individual case to be able to provide insightful advice and guidance.”

ADVOCACY

Hospital Liaison Services

Dedicated Case Workers

MARS advisors bridge the gap between patients Medical emergencies don’t follow office hours— and medical teams—advocating within hospitals neither does MARS. Our team is available 7/24 to ensure clear communication, appropriate around the clock, providing urgent support and care, and sensitivity to each patient’s medical real-time advocacy to help patients access the and cultural needs. care they need, when they need it most.

Appointment Expediting

When receptionists say ‘no openings for weeks,’ MARS works with medical staff to secure expedited slots.

DIAGNOSTICS

Direction

When patients receive alarming news from their GP, MARS steps in to arrange early diagnostic tests, ensuring swift decisions and timely specialist care.

Emotion

Reducing uncertainty by expediting tests significantly improves patients' and families' well-being, alleviating stress and anxiety.

Speed

Waiting weeks or months for NHS appointments can be detrimental—MARS fast-tracks diagnostics so treatment can begin when every day counts.

Funding

In select life-threatening cases, for those unable to afford private diagnostics, MARS provides financial assistance and facilitates continued treatment under the NHS, ensuring no one is left without care.

8 // Trustees Annual Report

Year Ended 31 December 2024 // 9

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

Mr. Alan Farthing, MD FRCOG

SUPPORT

prescriptions in Stamford Hill and Golders Green—minimizing travel and easing decision-making. These centres have encouraged more people to seek urgent care on Yom Tov, proving lifesaving for m a n y.

Dedicated Case Workers

Patients with long-term conditions receive a dedicated case worker providing continuous, personalised support throughout their medical journey.

Financial Aid

Medical Transfers

In potential life-threatening cases, MARS covers medical costs to expedite diagnosis. In select cases, Mars funds an expert second opinion, ensuring finances never stand in the way of top-quality care.

MARS arranges safe national transfers by ambulance and international transfers by air for specialized treatment, handling logistics, transfer bureaucracy and funding where applicable.

Obtaining Medical Records

Interpretation

MARS simplifies medical MARS guides patients on how to terminology for those retrieves past test results, facing language scans, and reports— barriers, vital clues for ensuring doctors and patients fully researchers. understand Technical their care. Navigators Yom-Tov From video VAY '] EZ Clinics calls with To ensure doctors to access managing to urgent patient medical portals and care on Yom complex Tov, MARS forms, MARS established , handles the technical free walk-in GP details that save centres with l i v e s .

Consultant Gynecological Surgeon and Oncologist, Imperial NHS Trust

“I have been giving advice to MARS patients for the last five years and have always been impressed by the careful attention to detail by the Medical Director and his team. In my experience, they are determined to understand the logic behind any recommendations, to ensure there are no better alternatives and to make sure the patient is pointed towards the right practitioner for treatment. It is a level of service that others should aspire to.”

our specialized divisions

==> picture [423 x 230] intentionally omitted <==

----- Start of picture text -----
Complex Critical
Cardiology Pediatrics
Care
Dermatology Endocrinology ENT
Fetal
Medicine Gastroenterology Hematology
Neurology OB-GYN Ophthalmology
# 2S a
Renal &
Orthopedics Respiratory
Urology
Rheumatology Surgical
----- End of picture text -----

Our Oncology Divisions

10 // Trustees Annual Report

// 11

Year Ended 31 December 2024

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

Accomplishments in 2024

n International transfers

n Working hand-in-hand with medical organisations in the community

Assisting patients that require medical transfers overseas to receive appropriate treatment, includes organising many logistics and coordinating medical teams and flight operators form around the globe. As the need for these transfers have become more frequent, we have established a special team in Mars that specialises in arranging these transfers from A-Z in the most efficient and comfortable manner for the patient and their family, as well minimising the material costs involved.

We have launched a series of lectures titled ‘Beyond the A&E‘, hosted by Mars and presented by renowned consultants in a variety of medical specialties, to other medical organisations in the community that work alongside Mars, like Hatzola etc.

These lectures deepened the relationship Mars has with other community organisations and gives them a deeper understanding of what happens with patients after handover, so we can together achieve the best outcome for a patient.

n Global Cancer Research

The demand for our Oncology department services is unfortunately increasing on a weekly basis with many complex cases; we invested in vast global research and established strong links with equivalent international organisations and medical institutions enabling us to do the utmost possible to achieve better outcomes for our patients.

n Cultural Sensitivity Awards

Following time and effort we have invested in cultural training and awareness in various London’s major medical centres, Mars held an appreciation event for the Cardiac ICU, Paediatric ICU and Neonatal ICU departments at Great Ormond Street Hospital for Children. Mars presented each of the three departments with an ‘Excellence in Cultural Sensitivity’ Award, in recognition of the respect, sensitivity and outstanding compassion they have nt... shown towards the religious and cultural needs of patients within the Om community.

n Switched to paperless

We aim to look after the global environment as part of our mission to help the people living in it. We invested in efficient software and programs for data storage and medical records sharing in our office, complying with the GDPR rules and regulations, and digitalised our work to minimise the use of paper.

n Better understanding in treatment option

Mars staff attended many medical conferences, lectures and symposiums hosted by respectful medical centres in London including UCLH, Cleveland Clinic, King’s College Hospital, Guy’s Hospital and The London Clinic, covering various topics including GI & Obstetrics, Stroke & Cardiac, Renal Issues, Complex Diabatic and more that are relevant to our departments.

going forward

that need help in paying for their medical bills.

n Keeping up to date

As requests for our help from members in the community is continuously increasing, and these include many more complex cases in numerous conditions, we aim to visit treatment facilities across London, as well invite them to Mars’s headquarters, for them to showcase and demonstrate new innovations and treatment methods to the Mars staff to learn and experience firsthand all kinds of treatment options, discover what’s new, so we are always being up to date with the latest the medical world has to offer.

n Collaborating with international organisations

Mars is finding itself increasingly connecting and sharing cases with international organisations in order to reach the best outcomes for patients. We will invite the heads and leaders of those organisations to visit our offices, as well fly overseas to meet them, getting to personally know the staff members and by sharing information and insights will result in achieving the best possible outcomes by deepening connections and collaborations with those international organisations.

n Training programs

To keep to our mission of always being aware and up to date with the best the medical world has to offer, our staff will attend and actively participate in training programs, lectures and discussion forums of various medical conditions so that we can always help our patients with the best care available and possible for them.

n New developments feedback

Mars being in the centre between patients and their medical teams, we continuously find ourselves receiving patient’s feedback on new treatments and how new developments impact the patients. we will therefore, from a patient advocacy viewpoint, present this feedback to relevant stakeholders giving them the opportunities to develop their products to the best standards.

n Private care pricing

Although Mars massively encourages the community to make sure they are covered by private medical insurance, we still experience many patients that require help in the private sector that are not fully covered, especially when it comes to diagnosis and detecting illness in time, or when in need of a second opinion when time is of the essence. Therefore, we aim to have discussions with those private providers that we find we refer a large majority of our patients, to negotiate discounts and better pricing for those

n Mental health training

Given the nature of our work of dealing with illness and hardship, Mars will provide adequate mental health training sessions to its staff members and volunteers, to make sure they are all stable and fit to do their job with efficiency and fully being out there for the patients supporting and helping them with a clear mind.

These events enhanced the knowledge and learning of our staff, developing a better understanding of treatment options to ensure better access to available treatments when necessary.

Ww Year Ended 31 December 2024

12 // Trustees Annual Report

// 13

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

Mr. Christopher Chan

facts & figures

250+ 30 Calls every day Resolute staff 3,203 17 402 New Cases in the Emergency diagnostics and Medical divisions consultations funded by past year MARS in the past year 12 Oncology divisions

Consultant colorectal surgeon BSc PhD FRCS Royal London Hospital

“MARS, under the direction of Rabbi Grunfeld, is an outstanding service that has helped an innumerable number of patients over the years. The assistance they provide is something above and beyond that of current medical services. I believe that patients have truly benefited from such a bespoke service, as MARS not only facilitates, but also identifies, the deemed best medical specialist for the patient’s needs.”

Don’t go it alone. We’re here to help.

14 // Trustees Annual Report

// 15

Year Ended 31 December 2024

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

Evaluation & Feedback

We measure outcomes based on feedback from service users, medical professionals (as on our website) and local community leaders. We use this feedback to refine and improve our services for current and future patients.

We recognise that it is difficult to conduct personal interviews and gather survey responses from patients and their families during their time of crisis. Aside for it being an inappropriate time

to approach beneficiaries, a majority will prefer anonymity and are reluctant to expose their struggles.

Where possible, we encourage beneficiaries to keep us updated via email, letter or phone call. We record all feedback, complaints and queries in line with GDPR and monitor our services accordingly. These are presented and discussed in our monthly management meetings.

n n n

THANK YOU

We owe immense gratitude to our devoted members in the community who work tirelessly behind the scenes to share the burden of Rabbi Grunfeld, ensure that we have the necessary funds, and offer their assistance in times of need.

On behalf of our staff, volunteers and

beneficiaries we would like to thank our donors. Your generous support has helped us be there for our community at critical times and give them the emotional and practical support when they needed it most. We pray for better times, both locally and globally and hope that you will be in a position to continue supporting this much needed service.

n n n

16 // Trustees Annual Report

Year Ended 31 December 2024 // 17

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

TRUSTEES’ ANNUAL REPORT (INCORPORATING THE DIRECTORS’ REPORT) (continued)

YEAR ENDED 31 DECEMBER 2024

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

TRUSTEES’ ANNUAL REPORT (INCORPORATING THE DIRECTORS’ REPORT) (continued)

YEAR ENDED 31 DECEMBER 2024

TRUSTEES' RESPONSIBILITIES STATEMENT

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, its memorandum and articles of association, and constitutes a limited company, limited by guarantee, as defined by Companies Act 2006.

Recruitment and appointment of new trustees

It is not currently the intention of the trustees of the charity to appoint new trustees. Should this situation change in the future, the trustees will apply suitable recruitment and training procedures.

Risk Management

The trustees have identified and reviewed the major risks to which the charity is exposed, in particular those related to the operations and finance of the charity, and are satisfied that systems are in place to mitigate those risks.

PUBLIC BENEFIT

The trustees confirm that they have referred to the guidance contained in the Charity Commission's general guidance on public benefit, when reviewing the charity's aims and objectives, and in planning future activities and setting grant making policy for the year.

MARS serves people from ethnic minority communities, focusing particularly, but not exclusively, on the Orthodox Jewish Community. This community has unique religious and cultural needs that may be unfamiliar to the medical world. This community also includes recent immigrants to the UK, meaning that both the language and the culture are unfamiliar to them.

Geographically, we are based in London, but we receive calls from all over England and have liaison officers located in other areas of the UK such as Essex, Manchester and Gateshead.

The trustees, who are also directors for the purposes of company law, are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the charity trustees to prepare financial statements for each year which give a true and fair view of the state of affairs of the charitable company and the incoming resources and application of resources, including the income and expenditure, for that period.

In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

AUDITOR

FINANCIAL REVIEW

The financial position of the Charity is satisfactory.

Income and donations aggregate £1,595,687. Total resources expended were £1,570,081 resulting in a net surplus of £25,606 for the year and total reserves of £384,030 (2023: £358,424).

RESERVES POLICY

The Trustees have examined the charity's requirements for reserves in light of the main risks to the organisation. It has established a policy whereby the unrestricted funds not committed or invested in tangible fixed assets held by the charity should be between 3 and 6 months of the expenditure. Budgeted expenditure for 2025 is £1.2m and therefore the target is £300,000 to £600,000 in unrestricted reserve funds. The reserves are needed to meet the working capital requirements of the charity and the Management Committee are confident that at this level they would be able to continue the current activities of the charity in the event of a significant drop in funding. The present level of unrestricted reserves available to the charity of £326,000 therefore falls within this target level.

Each of the persons who is a trustee at the date of approval of this report confirms that:

The auditor is deemed to have been re-appointed in accordance with section 487 of the Companies Act 2006.

SMALL COMPANY PROVISIONS

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

27/10/2025 The trustees' annual report was approved on .............................. and signed on behalf of the board of trustees by:

Mr H Grunfeld Trustee

18 // Trustees Annual Report

Year Ended 31 December 2024 // 19

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF MARS ORG. LTD YEAR ENDED 31 DECEMBER 2024

OPINION

We have audited the financial statements of MARS ORG. LTD (the 'charity') for the year ended 31 December 2024 which comprise the statement of financial activities (including income and expenditure account), statement of financial position, statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF MARS ORG. LTD (continued) YEAR ENDED 31 DECEMBER 2024

information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINIONS ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of the knowledge and understanding of the charity and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Act 2011 requires us to report to you if, in our opinion:

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The other information comprises the information included in the annual report, other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other

20 // Annual Report

Year Ended 31 December 2024 // 21

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF MARS ORG. LTD (continued)

YEAR ENDED 31 DECEMBER 2024

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

• We obtained an understanding of the legal and regulatory frameworks that are applicable to the company, and determined that the most relevant to the presentation of the financial statements are those that relate to the reporting legislation (UK GAAP and the Companies Act 2006), the relevant tax regulations in the United Kingdom, the Landlord and Tenant Act, the UK General Data Protection Regulation (GDPR), Health & Safety Regulations and the Bribery Act. We understood how the company is complying with those frameworks through discussion with the trustees and senior management, and by identifying the company's policies and procedures regarding compliance with laws and regulations. We also identified those members of management who have the primary responsibility for ensuring compliance with laws and regulations, and for reporting any known instances of non-compliance to the trustees. We communicated these identified frameworks amongst our audit team and remained alert to any indications of non-compliance throughout the audit. We ensured that the engagement team had sufficient competence and capability to identify or recognise non-compliance with laws and regulations.

• We assessed the susceptibility of the company's financial statements to material misstatement, including how fraud might occur, by reviewing the company's identified risks and enquiry with the trustees and senior management during the planning and finalisation phases of our audit. The susceptibility to such material misstatement was determined to be low.

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF MARS ORG. LTD (continued)

YEAR ENDED 31 DECEMBER 2024

• Based on this understanding we designed our audit procedures to identify non-compliance with the identified legal and regulatory frameworks, which were part of our procedures on the related financial statement items. Our procedures included reviewing the company's internal controls policies and procedures, reviewing the minutes of board meetings and correspondence with regulatory bodies including HMRC, testing transactions outside the normal course of the business and journal entries, and discussions with the trustees and senior management.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing noncompliance and cannot be expected to detect non-compliance with all laws and regulations.

As part of an audit in accordance with ISAs (UK), we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

22 // Annual Report

Year Ended 31 December 2024 // 23

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF MARS ORG. LTD (continued)

YEAR ENDED 31 DECEMBER 2024

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

STATEMENT OF FINANCIAL ACTIVITIES

(INCLUDING INCOME AND EXPENDITURE ACCOUNT) YEAR ENDED 31 DECEMBER 2024

USE OF OUR REPORT

This report is made solely to the charity's members, as a body, in accordance with section 144 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charity's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's members as a body, for our audit work, for this report, or for the opinions we have formed.

David Goldberg (Senior statutory auditor)

Cohen Arnold

New Burlington House 1075 Finchley Road London NW11 0PU

Chartered accountants & statutory auditor

27/10/2025

2024 2023
Unrestricted Restricted
funds funds Total funds Total funds
Note £ £ £ £
Income and endowments
Donations and legacies 5 1,311,738 282,930 1,594,668 1,451,213
Investment income 7 1,019 – 1,019 498
----------------------------------------------- ------------------------------------- ----------------------------------------------- -----------------------------------------------
Total income 1,312,757 282,930 1,595,687 1,451,711
=============================================== ===================================== =============================================== ===============================================
Expenditure
Expenditure on raising funds:
Costs of raising donations and Costs of raising donations and
legacies 8 (139,943) – (139,943) (109,023)
Expenditure on charitable activities 9,10 (1,111,440) (318,698) (1,430,138) (1,332,755)
----------------------------------------------- ------------------------------------- ----------------------------------------------- -----------------------------------------------
Total expenditure (1,251,383) (318,698) (1,570,081) (1,441,778)
=============================================== ===================================== =============================================== ===============================================
----------------------------------------------- ------------------------------------- ----------------------------------------------- -----------------------------------------------
Net income and net movement in funds Net income and net movement in funds 61,374 (35,768) 25,606 9,933
=============================================== ===================================== =============================================== ===============================================
Reconciliation of funds
Total funds brought forward 265,185 93,239 358,424 348,491
----------------------------------------------- ------------------------------------- ----------------------------------------------- -----------------------------------------------
Total funds carried forward 326,559
===============================================		 57,471
=====================================		 384,030
===============================================		 358,424
===============================================

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The notes on pages 28 to 35 form part of these financial statements.

24 // Annual Report

Year Ended 31 December 2024 // 25

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

31 DECEMBER 2024

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE STATEMENT OF FINANCIAL POSITION

2024 2023
Note £ £ £ £
FIXED ASSETS
Tangible fixed assets 16 224,828 233,308
CURRENT ASSETS
Debtors 17 - 49,307
Cash at bank and in hand 197,883 124,076
------------------------------------- -------------------------------------
197,883 173,383
CREDITORS: amounts falling due
within one year 18 (16,460) (26,598)
------------------------------------- -------------------------------------
NET CURRENT ASSETS 181,423 146,785
------------------------------------- -------------------------------------
TOTAL ASSETS LESS CURRENT
LIABILITIES 406,251 380,093
CREDITORS: amounts falling due
after more than one year 19 (22,221) (21,669)
------------------------------------- -------------------------------------
NET ASSETS 384,030 358,424
===================================== =====================================
FUNDS OF THE CHARITY
Restricted funds 57,471 93,239
Unrestricted funds 326,559 265,185
------------------------------------- -------------------------------------
Total charity funds 20 384,030
=====================================		 358,424
=====================================

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

These financial statements were approved by the board of trustees and authorised for issue on ........................, and are signed on behalf of the board by:27/10/2025

[+ GRUMRELO Mr H Grunfeld Trustee

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE STATEMENT OF CASH FLOWS YEAR ENDED 31 DECEMBER 2024

2024 2023
£ £
CASH FLOWS FROM OPERATING ACTIVITIES
Net income 25,606 9,933
Adjustments for:
Depreciation of tangible fixed assets 11,716 14,798
Other interest receivable and similar income (1,019) (498)
Interest payable and similar charges 2,709 4,099
Changes in:
Trade and other debtors 49,307 (22,768)
Trade and other creditors (5,037) 3,077
------------------------------- -------------------------------
Cash generated from operations 83,282 8,641
Interest paid (2,709) (4,099)
Interest received 1,019 498
------------------------------- --------------------------
Net cash from operating activities 81,592 5,040
=============================== ==========================
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of tangible assets (3,236) (53,845)
------------------------------- -------------------------------
Net cash used in investing activities (3,236) (53,845)
=============================== ===============================
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from borrowings (4,549) (3,572)
------------------------------- -------------------------------
Net cash used in financing activities (4,549) (3,572)
=============================== ===============================
NET INCREASE/(DECREASE) IN CASH AND CASH
EQUIVALENTS 73,807 (52,377)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 124,076 176,453
------------------------------------- -------------------------------------
CASH AND CASH EQUIVALENTS AT END OF YEAR 197,883
=====================================		 124,076
=====================================

The notes on pages 28 to 35 form part of these financial statements.

The notes on pages 28 to 35 form part of these financial statements.

26 // Annual Report

Year Ended 31 December 2024 // 27

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2024

1. GENERAL INFORMATION

The charity is a public benefit entity and a private company limited by guarantee, registered in England and Wales and a registered charity in England and Wales. The address of the registered office is New Burlington House, 1075 Finchley Road, London, NW11 0PU, United Kingdom.

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in compliance with FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland', the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (Charities SORP (FRS 102)) and the Companies Act 2006.

3. ACCOUNTING POLICIES

Basis of preparation

The financial statements have been prepared on the historical cost basis.

The financial statements are prepared in sterling, which is the functional currency of the entity.

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 DECEMBER 2024

3. ACCOUNTING POLICIES (continued)

Resources expended

All expenditure is classified under the Charity's principal categories of charitable and other expenditure and by the type of expense.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other recognised gains and losses, unless it reverses a charge for impairment that has previously been recognised as expenditure within the statement of financial activities. A decrease in the carrying amount of an asset as a result of revaluation, is recognised in other recognised gains and losses, except to which it offsets any previous revaluation gain, in which case the loss is shown within other recognised gains and losses on the statement of financial activities.

Depreciation

Going concern

There are no material uncertainties about the charity's ability to continue.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

There have been no material adjustments based on estimations and assumptions during the financial year.

Fund accounting

General unrestricted funds comprise the accumulated surplus or deficit on income and expenditure account. They are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity.

Restricted funds are funds subject to specific restricted conditions imposed by donors. There are no restricted funds as at the Balance Sheet date.

Designated funds are funds which have been set at the discretion of the Trustees for specific purposes. There are no designated funds as at the Balance Sheet date.

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the amount receivable or payable including any related transaction costs, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Current assets and current liabilities are subsequently measured at the cash or other consideration expected to be paid or received and not discounted.

4. LIMITED BY GUARANTEE

The charity is a company limited by guarantee and has no share capital. The liability of each trustee in the event of winding up is limited to £1.

Incoming resources

All donations are recognised in the statement of financial activities (SOFA) of the charity when received. All other income is recognised on a receivable basis.

28 // Annual Report

Year Ended 31 December 2024 // 29

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 DECEMBER 2024

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 DECEMBER 2024

9. EXPENDITURE ON CHARITABLE ACTIVITIES BY FUND TYPE

5. DONATIONS AND LEGACIES

Unrestricted Restricted Total Funds
Funds Funds 2024
£ £ £
DONATIONS
Donations 1,292,572 282,930 1,575,502
GRANTS
Grants 19,166 – 19,166
----------------------------------------------- ------------------------------------- -----------------------------------------------
1,311,738 282,930 1,594,668
=============================================== ===================================== ===============================================
Unrestricted Restricted Total Funds
Funds Funds 2023
£ £ £
DONATIONS
Donations 1,279,440 37,807 1,317,247
GRANTS
Grants – 133,966 133,966
----------------------------------------------- ------------------------------------- -----------------------------------------------
1,279,440 171,773 1,451,213
=============================================== ===================================== ===============================================
ANALYSIS OF GRANTS RECEIVED
Donations received, included in the above, are as follows:
2024 2023
£ £
Special case fund 282,930
=====================================		 133,966
=====================================

6. ANALYSIS OF GRANTS RECEIVED

7. INVESTMENT INCOME

Unrestricted Total Funds Unrestricted Total Funds Funds 2024 Funds 2023 £ £ £ £ Bank interest receivable 1,019 1,019 498 498 ========================== ========================== ================ ================ COSTS OF RAISING DONATIONS AND LEGACIES Unrestricted Total Funds Unrestricted Total Funds Funds 2024 Funds 2023 £ £ £ £ Fundraising costs 139,943 139,943 109,023 109,023 ===================================== ===================================== ===================================== =====================================

8. COSTS OF RAISING DONATIONS AND LEGACIES

Unrestricted Restricted Total Funds
Funds Funds 2024
£ £ £
Charitable activities 1,071,074 318,698 1,389,772
Support costs 40,366 – 40,366
----------------------------------------------- ------------------------------------- -----------------------------------------------
1,111,440 318,698 1,430,138
=============================================== ===================================== ===============================================
Unrestricted Restricted Total Funds
Funds Funds 2023
£ £ £
Charitable activities 1,098,925 167,252 1,266,177
Support costs 49,340 17,238 66,578
----------------------------------------------- ------------------------------------- -----------------------------------------------
1,148,265
===============================================		 184,490
=====================================		 1,332,755
===============================================

10. EXPENDITURE ON CHARITABLE ACTIVITIES BY ACTIVITY TYPE

Activities Activities
undertaken undertaken Total funds Total fund
directly Support costs 2024 2023
£ £ £ £
Charitable activities 1,389,772 23,912 1,413,684 1,316,075
Governance costs – 16,454 16,454 16,680
----------------------------------------------- ------------------------------- ----------------------------------------------- -----------------------------------------------
1,389,772
===============================================		 40,366
===============================		 1,430,138
===============================================		 1,332,755
===============================================

11. ANALYSIS OF CHARITABLE ACTIVITIES

ANALYSIS OF CHARITABLE ACTIVITIES
2024 2023
£ £
Charitable Activities 446,897 375,176
Special case fund 401,430 365,451
Medical Support 172,413 240,632
Holiday (Yom Tov) clinics 26,899 28,480
Health awareness 84,141 101,610
Sustenance packages 96,486 88,470
Medical research 161,506 66,358
----------------------------------------------- -----------------------------------------------
1,389,772
===============================================		 1,266,177
===============================================

30 // Annual Report

Year Ended 31 December 2024 // 31

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 DECEMBER 2024

12. ANALYSIS OF SUPPORT COSTS

ANALYSIS OF SUPPORT COSTS
Charitable
activities Total 2024 Total 2023
£ £ £
Finance costs 2,709 2,709 4,100
Governance costs 13,744 13,744 12,580
Legal and professional fees 12,197 12,197 35,100
Depreciation 11,716 11,716 14,798
------------------------------- ------------------------------- -------------------------------
40,366
===============================		 40,366
===============================		 66,578
===============================

13. NET INCOME

Net income is stated after charging/(crediting):

NET INCOME
Net income is stated after charging/(crediting):
2024 2023
£ £
Depreciation of tangible fixed assets 11,716 14,798
Fees payable for the audit of the financial statements 13,744
===============================		 12,580
===============================

14. STAFF COSTS

STAFF COSTS
2024 2023
£ £
Wages and salaries 261,685 220,930
Social security costs 4,326 5,713
------------------------------------- -------------------------------------
266,011
=====================================		 226,643
=====================================

The average monthly number of employees during the year was 27 (2023: 28).

No salaries of £60,000 or over were paid during the year.

15. TRUSTEE REMUNERATION AND EXPENSES

No remuneration or other benefits from employment with the charity or a related entity were received by the trustees.

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 DECEMBER 2024

16. TANGIBLE FIXED ASSETS

16. TANGIBLE FIXED ASSETS
Land and Fixtures and
buildings fittings Equipment Total
£ £ £ £
Cost
At 1 January 2024 187,703 45,801 66,458 299,962
Additions – – 3,236 3,236
------------------------------------- ------------------------------- ------------------------------- -------------------------------------
At 31 December 2024 187,703 45,801 69,694 303,198
===================================== =============================== =============================== =====================================
Depreciation
At 1 January 2024 – 21,552 45,102 66,654
Charge for the year – 3,669 8,047 11,716
------------------------------------- ------------------------------- ------------------------------- -------------------------------------
At 31 December 2024 – 25,221 53,149 78,370
===================================== =============================== =============================== =====================================
Carrying amount
At 31 December 2024 187,703 20,580 16,545 224,828
===================================== =============================== =============================== =====================================
At 31 December 2023 187,703 24,249 21,356 233,308
===================================== =============================== =============================== =====================================
17. DEBTORS
2024 2023
£ £
Other debtors -
===============================		 49,307
===============================

18. CREDITORS: amounts falling due within one year

2024 2023
£ £
Bank loans and overdrafts 4,500 9,601
Social security and other taxes 1,998 1,268
Other creditors 9,962 15,729
-------------------------------
16,460		 -------------------------------
26,598
=============================== ===============================
CREDITORS: amounts falling due after more than one year
2024 2023
£ £
Bank loans and overdrafts 22,221
===============================		 21,669
===============================

19. CREDITORS: amounts falling due after more than one year

32 // Annual Report

Year Ended 31 December 2024 // 33

Docusign Envelope ID: 643DEC51-06C3-496E-A73C-3DE39A8D3431

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS (continued)

YEAR ENDED 31 DECEMBER 2024

20. ANALYSIS OF CHARITABLE FUNDS

Unrestricted funds

Unrestricted funds
At 1 At 31
January December
2024 Income Expenditure 2024
£ £ £ £
General funds 265,185 1,312,757 (1,251,383) 326,559
===================================== =============================================== =============================================== =====================================
At 1 At 31
January December
2023 Income Expenditure 2023
£ £ £ £
General funds 242,535 1,279,938 (1,257,288) 265,185
===================================== =============================================== =============================================== =====================================
Restricted funds
At 1 At 31
January December
2024 Income Expenditure 2024
£ £ £ £
Restricted Fund 93,239 282,930 (318,698) 57,471
=============================== ===================================== ===================================== ===============================
At 1 At 31
January December
2023 Income Expenditure 2023
£ £ £ £
Restricted Fund 105,956
=====================================		 171,773
=====================================		 (184,490)
=====================================		 93,239
===============================

MARS ORG. LTD

COMPANY LIMITED BY GUARANTEE

NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 DECEMBER 2024

21. ANALYSIS OF NET ASSETS BETWEEN FUNDS

Unrestricted Restricted Total Funds
Funds Funds 2024
£ £ £
Tangible fixed assets 224,828 – 224,828
Current assets 140,412 57,471 197,883
Creditors less than 1 year (16,460) – (16,460)
Creditors greater than 1 year (22,221) – (22,221)
------------------------------------- ------------------------------- -------------------------------------
Net assets 326,559 57,471 384,030
===================================== =============================== =====================================
Unrestricted Restricted Total Funds
Funds Funds 2023
£ £ £
Tangible fixed assets 233,308 – 233,308
Current assets 80,144 93,239 173,383
Creditors less than 1 year (26,598) – (26,598)
Creditors greater than 1 year (21,669) – (21,669)
------------------------------------- ------------------------------- -------------------------------------
Net assets 265,185 93,239 358,424
===================================== =============================== =====================================
ANALYSIS OF CHANGES IN NET DEBT
At At
1 Jan 2024 Cash flows 31 Dec 2024
£ £ £
Cash at bank and in hand 124,076 73,807 197,883
Debt due within one year (9,601) 5,101 (4,500)
Debt due after one year (21,669) (552) (22,221)
------------------------------------- ------------------------------- -------------------------------------
92,806
=====================================		 78,356
===============================		 171,162
=====================================

22. ANALYSIS OF CHANGES IN NET DEBT

23. RELATED PARTIES

There have been no related party transactions in the reporting period that require disclosure.

34 // Annual Report

Year Ended 31 December 2024 // 35